• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    PRESIDENT & CEO Lalwani Nikhil covered exercise/tax liability with 17,455 shares, decreasing direct ownership by 4% to 468,179 units (SEC Form 4)

    3/25/25 4:47:48 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANIP alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Lalwani Nikhil

    (Last) (First) (Middle)
    C/O ANI PHARMACEUTICALS, INC.
    210 MAIN STREET WEST

    (Street)
    BAUDETTE MN 56623

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ANI PHARMACEUTICALS INC [ ANIP ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    PRESIDENT & CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    03/23/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/23/2025 F(1) 17,455 D $64.26 468,179 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 34,124 shares of restricted stock, the grant of which was previously reported.
    Remarks:
    /s/ Nikhil Lalwani, by attorney-in-fact Meredith W. Cook 03/25/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ANIP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANIP

    DatePrice TargetRatingAnalyst
    3/14/2025$80.00Buy
    Jefferies
    3/12/2025$85.00Overweight
    Analyst
    12/11/2024$80.00Outperform
    Leerink Partners
    10/11/2024$68.00Overweight
    Piper Sandler
    3/15/2024$80.00Overweight
    CapitalOne
    8/22/2023$60.00 → $73.00Buy
    H.C. Wainwright
    3/1/2023$55.00Buy
    Guggenheim
    9/7/2022$50.00Buy
    H.C. Wainwright
    More analyst ratings

    $ANIP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $27,584 worth of shares (400 units at $68.96), decreasing direct ownership by 0.50% to 80,145 units (SEC Form 4)

      4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

      4/14/25 4:17:11 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT & CEO Lalwani Nikhil covered exercise/tax liability with 17,455 shares, decreasing direct ownership by 4% to 468,179 units (SEC Form 4)

      4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

      3/25/25 4:47:48 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP & CFO Carey Stephen P. covered exercise/tax liability with 6,210 shares, decreasing direct ownership by 3% to 180,863 units (SEC Form 4)

      4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

      3/25/25 4:44:49 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    Financials

    Live finance-specific insights

    See more
    • ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

      Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4%Total Rare Disease quarterly net revenues of $69.0 million, which includes: Purified Cortrophin® Gel net revenues of $52.9 million, an increase of 43.1% year-over-year, andILUVIEN® and YUTIQ® net revenues of $16.1 million Record Generics net revenues of $98.7 million, an increase of 40.5% year-over-yearDelivered record quarterly adjusted non-GAAP EBITDA of $50.7 million, an increase of 34.9% year-over-yearDiluted GAAP income per share of $0.69 and record adjusted non-GAAP diluted earnings per share of $1.70Increased 2025 guidance with expected net revenues of $768.0 million to $793.0 million

      5/9/25 6:50:08 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET

      PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: DateFriday, May 9, 2025 Time8:00 a.m. ET Toll free (U.S.)800-225-9448 Conference ID4921902 Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section           A re

      4/9/25 6:50:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance

      Generated record quarterly net revenues of $190.6 million, representing year-over-year growth of 44.8%Total Rare Disease quarterly net revenue of $87.0 million, which includes: Record quarterly net revenue for Purified Cortrophin® Gel of $59.4 million, an increase of 42.3% year-over-year, andILUVIEN® and YUTIQ® net revenues of $27.6 million in the first full quarter of ownership following the acquisition of Alimera Sciences Delivered record quarterly adjusted non-GAAP EBITDA of $50.0 million, an increase of 65.7% year-over-yearDiluted GAAP loss per share of $(0.55) and adjusted non-GAAP diluted earnings per share of $1.63Increased 2025 guidance with expected net revenu

      2/28/25 6:50:16 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

      Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4%Total Rare Disease quarterly net revenues of $69.0 million, which includes: Purified Cortrophin® Gel net revenues of $52.9 million, an increase of 43.1% year-over-year, andILUVIEN® and YUTIQ® net revenues of $16.1 million Record Generics net revenues of $98.7 million, an increase of 40.5% year-over-yearDelivered record quarterly adjusted non-GAAP EBITDA of $50.7 million, an increase of 34.9% year-over-yearDiluted GAAP income per share of $0.69 and record adjusted non-GAAP diluted earnings per share of $1.70Increased 2025 guidance with expected net revenues of $768.0 million to $793.0 million

      5/9/25 6:50:08 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model

      Demonstrated Dose Dependent Effect in EAU Presented in a podium presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2025 annual meeting PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced preclinical data on the use of Purified Cortrophin® Gel (repository corticotropin injection USP) (Cortrophin Gel) in an EAU mouse model. "In a preclinical model of autoimmune uveitis, Cortrophin Gel reduced levels of inflammatory molecules without stimulating an adverse immune response," said Mary Pao, MD, PhD, Chief Medical Officer of Rare Disease at ANI. "The results further support our understandin

      5/5/25 7:00:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET

      PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: DateFriday, May 9, 2025 Time8:00 a.m. ET Toll free (U.S.)800-225-9448 Conference ID4921902 Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section           A re

      4/9/25 6:50:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    SEC Filings

    See more
    • SEC Form 10-Q filed by ANI Pharmaceuticals Inc.

      10-Q - ANI PHARMACEUTICALS INC (0001023024) (Filer)

      5/9/25 6:57:59 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)

      5/9/25 6:55:20 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by ANI Pharmaceuticals Inc.

      DEFA14A - ANI PHARMACEUTICALS INC (0001023024) (Filer)

      5/8/25 9:15:39 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ANI Pharmaceuticals Inc.

      SC 13G/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)

      11/13/24 4:30:24 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ANI Pharmaceuticals Inc. (Amendment)

      SC 13D/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)

      3/14/24 7:30:38 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ANI Pharmaceuticals Inc.

      SC 13G - ANI PHARMACEUTICALS INC (0001023024) (Subject)

      2/13/24 4:58:56 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    Leadership Updates

    Live Leadership Updates

    See more
    • Alcami Announces CEO Transition

      Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries  DURHAM, N.C., Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the resignation of Bill Humphries. Alcami's Board Chair and former Chief Executive Officer Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations and a strong client-centric approach from a proven industry veteran. "On behalf of the Board, I'd like to express gratitude to Bill for his leadership

      1/13/25 11:12:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors

      -- Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience -- Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and specialty and retail pharmacy -- BAUDETTE, Minn., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the addition of Matthew J. Leonard, R.Ph. to its Board of Directors. Mr. Leonard brings more than 35 years of experience as an accomplished leader and innovator within the pharmaceutical industry. This appointment is effective immediately. "We are delighted to add Matthew (Matt) Leonard to our Board of Directors. With his deep leadershi

      8/23/23 6:50:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer

      ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") today announced that Krista L. Davis will join the Company as Chief Human Resources Officer, effective September 12. Ms. Davis brings to the Company over 20 years of executive leadership experience in human resources, talent management, and organizational development. "Ms. Davis is an important addition to our leadership team and will bring strategic and innovative thought leadership to our priority people and organizational issues. Krista has a long track record of driving organizational effectiveness and delivering results across industries and cultures, most recently with Novartis, where she led global human resources for

      9/12/22 6:50:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for HYDROCODONE BITARTRATE AND IBUPROFEN

      Submission status for ANI PHARMS INC's drug HYDROCODONE BITARTRATE AND IBUPROFEN (SUPPL-6) with active ingredient HYDROCODONE BITARTRATE; IBUPROFEN has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 077454, Application Classification: Labeling

      3/8/21 5:11:24 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OXYCODONE AND ASPIRIN

      Submission status for ANI PHARMS INC's drug OXYCODONE AND ASPIRIN (SUPPL-30) with active ingredient ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 040255, Application Classification: Labeling

      3/8/21 5:11:06 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for EZETIMIBE AND SIMVASTATIN

      Submission status for ANI PHARMS INC's drug EZETIMIBE AND SIMVASTATIN (SUPPL-10) with active ingredient EZETIMIBE; SIMVASTATIN has changed to 'Approval' on 02/23/2021. Application Category: ANDA, Application Number: 201890, Application Classification: Labeling

      2/25/21 5:09:42 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on ANI Pharma with a new price target

      Jefferies initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $80.00

      3/14/25 7:26:09 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Analyst initiated coverage on ANI Pharma with a new price target

      Analyst initiated coverage of ANI Pharma with a rating of Overweight and set a new price target of $85.00

      3/12/25 7:20:36 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on ANI Pharma with a new price target

      Leerink Partners initiated coverage of ANI Pharma with a rating of Outperform and set a new price target of $80.00

      12/11/24 7:21:57 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care